Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
442 studies found for:    DIABETIC MACULAR EDEMA
Show Display Options
Rank Status Study
1 Completed Glycemic Control and Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention: Other: Respond to therapy for diabetic macular edema
2 Completed A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)
Condition: Diabetic Macular Edema
Intervention: Drug: Teprotumumab
3 Unknown  Triple Therapy for Diffuse Diabetic Macular Edema
Condition: Diffuse Diabetic Macular Edema
Intervention: Procedure: Triple therapy for diffuse diabetic macular edema
4 Recruiting Identifying Patients With Unrecognized Treatable Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention:
5 Completed Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
Condition: Diabetic Macular Oedema
Intervention: Drug: Intravitreal injection of pegaptanib sodium
6 Completed Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema
Condition: Diabetic Macular Edema
Interventions: Drug: Bevacizumab;   Drug: Triamcinolone acetonide
7 Unknown  OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits
Conditions: Diabetes;   Diabetic Macular Edema;   Diabetic Retinopathy
Intervention: Device: OCT imaging
8 Recruiting Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
Condition: Diabetic Macular Oedema
Intervention: Drug: dexamethasone intravitreal implant
9 Unknown  Sub-threshold Photocoagulation of Diabetic Macular Oedema
Condition: Diabetic Macular Oedema
Interventions: Device: PASCAL Laser, Green Laser 0.75;   Device: PASCAL Laser, Green Laser 1;   Device: PASCAL Laser, 70% Yellow Laser 0.75;   Device: PASCAL Laser, 70% Yellow Laser 1;   Device: PASCAL Laser, 40% Yellow Laser 0.75;   Device: PASCAL Laser, 40% Yellow Laser 1
10 Withdrawn Safety Study of ALG- 1001 to Treat Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention: Drug: ALG-1001
11 Completed
Has Results
Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion
Condition: Diabetic Macular Edema
Interventions: Drug: intravitreal injection of ranibizumab;   Procedure: peripheral laser;   Drug: intravitreal injection of triamcinolone acetonide;   Procedure: macular laser
12 Completed Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)
Condition: Diabetic Macular Edema
Interventions: Procedure: Laser photocoagulation;   Drug: Intravitreal triamcinolone;   Drug: Intravitreal bevacizumab
13 Completed Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention:
14 Completed Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema
Conditions: Diabetic Macular Edema;   Macular Edema, Cystoid;   Vision Disorders;   Clinically Significant Macular Edema
Intervention: Drug: long acting intravitreal dexamethasone implant
15 Completed The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention: Drug: Subconjunctival bevacizumab (Altuzan)
16 Recruiting 577nm Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema
Condition: Diabetic Macular Edema
Interventions: Device: 577-MPL;   Device: 532-SLP
17 Withdrawn Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing
Condition: Persistent Diabetic Macular Edema
Intervention: Drug: ranibizumab
18 Completed
Has Results
Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema
Condition: Diabetic Macular Edema
Interventions: Drug: Bevacizumab (Avastin);   Drug: Triamcinolone;   Drug: Sham;   Procedure: Lucentis
19 Completed Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention: Procedure: Intravitreal injection
20 Completed MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)
Condition: Diabetic Macular Edema
Interventions: Drug: Ranibizumab 0.05mg;   Drug: Ranibizumab 0.5mg

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.